ELM-PC5_2B | R Documentation |
Kaplan-Meier digitized data from ELM-PC5, figure 2B (PMID 25624429). A reported sample size of 1,099 for a primary endpoint of OS in prostate cancer.
`ELM-PC5_2B`
A data frame of 1,099 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (orteronel, placebo) | |
Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 33: 723–31.
summary(`ELM-PC5_2B`)
kmplot(`ELM-PC5_2B`)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.